Feature | April 01, 2013

Rox Medical Enrolls First U.K. Patients in CONTROL-HTN Hypertension Trial

April 1, 2013 — Rox Medical announced enrollment of the first U.K. patients in the CONTROL-HTN international randomized controlled trial of the Rox Flow procedure for the treatment of resistant hypertension. The first patients were enrolled at Eastbourne General Hospital, East Sussex, U.K. by doctors Neil Sulke and Stephan Furniss. For the two patients randomized to treatment, the Rox procedure was performed in the cardiac cath lab in under one hour.

"It was a very enjoyable and straightforward procedure on a patient with very difficult to control blood pressure," said Furniss. "The procedure was relatively painless and the patient showed significant improvement in blood pressure right after the procedure that we'll be anxious to monitor over the coming weeks and months. "This could be a very important new device treatment option for resistant hypertension patients," said Furniss. "We are anxious to enroll additional patients into this exciting trial."

"We like the fact that the Rox procedure is reversible and that it can treat patients who are not candidates or don't seem to respond to renal denervation," added Sulke. 

Rox Medical's Flow procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance and by diverting some arterial blood to the veins, adds lost compliance back into the vascular system. Uniquely, the Flow procedure only involves vascular structures away from vital organs like the kidneys, has an immediate effect and is fully reversible. The procedure also does not require heavy pain medications common to renal ablation techniques. The Rox procedure holds the promise of a meaningful long-term reduction in hypertension that may be combined with other device hypertension therapies.

The Rox Flow procedure for hypertension is not approved for use in the United States.

For more information: www.roxmedical.com

 

 

 

Related Content

News | Hypertension| August 27, 2015
August 27, 2015 — Analysis of blood samples from more than 5,000 people suggests that a more sensitive version of a b
ASE, echocardiography, hypertension, document, EACVI, JASE, Thomas H. Marwick
Feature | Cardiovascular Ultrasound| July 07, 2015
A new document from the American Society of Echocardiography (ASE) provides detailed guidance for clinicians on how to...
blood pressure, LDL, medication therapy, coronary plaque, SCAI
News | May 14, 2015
Combining statins for low-density lipoprotein (LDL) and calcium channel antagonists for blood pressure reduces harmful...
Medtronic, SYMPLICITY AF, PVI, renal denervation, Arctic Front, Spyral, G3
Feature | May 05, 2015
Medtronic plc announced the start of a clinical study to determine whether paroxysmal and persistent atrial...
Vessix Renal Denervation System, REDUCE-HTN: REINFORCE, high blood pressure

Vessix System image courtesy of Boston Scientific Corp.

News | May 04, 2015
Boston Scientific Corp. is taking a new approach to evaluate the performance of the Vessix Renal Denervation System,...
News | April 09, 2015
A study including more than 20,000 adults in China found combined use of the hypertension medication enalapril and...
Feature | April 01, 2015
Medtronic plc announced the initiation of the SPYRAL HTN Global Clinical Trial Program, a phased clinical program...
Renal denervation, hypertension, Peregrine System

Image courtesy of Ablative Solutions

News | February 12, 2015
Ablative Solutions Inc. announced the addition of Michael Weber, M.D., FACP, FACC, FAHA, to its Scientific Advisory...
blood pressure, systolic, hypertension, younger adults, cardiovascular, risk
News | February 10, 2015
Younger adults with elevated systolic blood pressure have a higher risk for cardiovascular disease and coronary heart...
Technology | February 05, 2015
Ostar Healthcare Technology announced the North American launch of their Cellular P201 telehealth blood pressure...
Overlay Init